ArticleThe American journal of pathology2016
Resolvin D3 and Aspirin-Triggered Resolvin D3 Are Protective for Injured Epithelia.
Article in The American journal of pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 53 citations in OpenAlex.
- Accelerated resolution of inflammation underlies sex differences in inflammatory responses in humans.The Journal of clinical investigation · 2017Trial
- Proresolving Lipid Mediators in the Respiratory System.Annual review of physiology · 2025Review
- The Potential of Fish Oil Components and Manuka Honey in Tackling Chronic Wound Treatment.Microorganisms · 2024Review
- The Antimicrobial and Antibiofilm Abilities of Fish Oil Derived Polyunsaturated Fatty Acids and Manuka Honey.Microorganisms · 2024Article
- The potential role of n-3 fatty acids and their lipid mediators on asthmatic airway inflammation.Frontiers in immunology · 2024Review
- Role of Resolvins in Inflammatory and Neuropathic Pain.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The role of peripheral inflammatory insults in Alzheimer's disease: a review and research roadmap.Molecular neurodegeneration · 2023Review
- Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators.Biochemical pharmacology · 2023Review
- Maresin-2 promotes mucosal repair and has therapeutic potential when encapsulated in thermostable nanoparticles.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- The Maresin 1-LGR6 axis decreases respiratory syncytial virus-induced lung inflammation.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- RvD1International journal of molecular sciences · 2022Article
- Human leukocytes selectively convert 4Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Role of specialized pro-resolving lipid mediators in pulmonary inflammation diseases: mechanisms and development.Respiratory research · 2021Review
- Specialized Pro-Resolving Mediators and the Lymphatic System.International journal of molecular sciences · 2021Review
- Review
- RvD1 Attenuated Susceptibility to Ischemic AKI in Diabetes by Downregulating Nuclear Factor-κ B Signal and Inhibiting Apoptosis.Frontiers in physiology · 2021Article
- Nutrition, immunity and COVID-19.BMJ nutrition, prevention & health · 2020Review
- COVID-19 - Toward a comprehensive understanding of the disease.Cardiology journal · 2020Review
- Role of Resolvins in the Inflammatory Resolution of Neurological Diseases.Frontiers in pharmacology · 2020Review
- Rhinovirus and Innate Immune Function of Airway Epithelium.Frontiers in cellular and infection microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
Acute lung injury is a life-threatening condition caused by disruption of the alveolar-capillary barrier leading to edema, influx of inflammatory leukocytes, and impaired gas exchange. Specialized proresolving mediators biosynthesized from essential fatty acids, such as docosahexaenoic acid, have tissue protective effects in acute inflammation. Herein, we found that the docosahexaenoic acid-derived mediator resolvin D3 (RvD3): 4S,11R,17S-trihydroxydocosa-5Z,7E,9E,13Z,15E,19Z-hexaenoic acid was present in uninjured lungs, and increased significantly 24 to 72 hours after hydrochloric acid-initiated injury. Because of its delayed enzymatic degradation, we used aspirin-triggered (AT)-RvD3: 4S,11R,17R-trihydroxydocosa-5Z,7E,9E,13Z,15E,19Z-hexaenoic acid, a 17R-epimer of RvD3, for in vivo experiments. Histopathological correlates of acid injury (alveolar wall thickening, edema, and leukocyte infiltration) were reduced in mice receiving AT-RvD3 1 hour after injury. AT-RvD3-treated mice had significantly reduced edema, as demonstrated by lower wet/dry weight ratios, increased epithelial sodium channel γ expression, and more lymphatic vessel endothelial hyaluronan receptor 1-positive vascular endothelial growth factor receptor 3-positive lymphatic vessels. Evidence for counterregulation of NF-κB by RvD3 and AT-RvD3 was seen in vitro and by AT-RvD3 in vivo. Increases in lung epithelial cell proliferation and bronchoalveolar lavage fluid levels of keratinocyte growth factor were observed with AT-RvD3, which also promoted cutaneous re-epithelialization. Together, these data demonstrate protective actions of RvD3 and AT-RvD3 for injured mucosa that accelerated restoration of epithelial barrier and function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.